| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
*
Research Department, Cantonal Hospital St. Gall, St. Gallen, Switzerland;
Max Delbrück Center for Molecular Medicine, Berlin-Buch, Germany;
Institute of Experimental Immunology, Department of Pathology, University Hospital Zurich, Zurich, Switzerland; and
§
Department of Molecular, Cellular, and Developmental Biology, Yale University, New Haven, CT 06520
The complete inhibition of proteasome activities interferes with the production of most MHC class I peptide ligands as well as with cellular proliferation and survival. In this study we have investigated how partial and selective inhibition of the chymotrypsin-like activity of the proteasome by the proteasome inhibitors lactacystin or epoxomicin would affect Ag presentation. At 0.5–1 µM lactacystin, the presentation of the lymphocytic choriomeningitis virus-derived epitopes NP118 and GP33 and the mouse CMV epitope pp89–168 were reduced and were further diminished in a dose-dependent manner with increasing concentrations. Presentation of the lymphocytic choriomeningitis virus-derived epitope GP276, in contrast, was markedly enhanced at low, but abrogated at higher, concentrations of either lactacystin or epoxomicin. The inhibitor-mediated effects were thus epitope specific and did not correlate with the degradation rates of the involved viral proteins. Although neither apoptosis induction nor interference with cellular proliferation was observed at 0.5–1 µM lactacystin in vivo, this concentration was sufficient to alter the fragmentation of polypeptides by the 20S proteasome in vitro. Our results indicate that partial and selective inhibition of proteasome activity in vivo is a valid approach to modulate Ag presentation, with potential applications for the treatment of autoimmune diseases and the prevention of transplant rejection.
This article has been cited by other articles:
|
|
 |
|
  M. Basler, C. Lauer, U. Beck, and M. Groettrup The Proteasome Inhibitor Bortezomib Enhances the Susceptibility to Viral Infection J. Immunol., November 15, 2009; 183(10): 6145 - 6150. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Diekmann, E. Adamopoulou, O. Beck, G. Rauser, S. Lurati, S. Tenzer, H. Einsele, H.-G. Rammensee, H. Schild, and M. S. Topp Processing of Two Latent Membrane Protein 1 MHC Class I Epitopes Requires Tripeptidyl Peptidase II Involvement J. Immunol., August 1, 2009; 183(3): 1587 - 1597. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Kiesel, Z. S. Buchwald, and R. Aurora Cross-Presentation by Osteoclasts Induces FoxP3 in CD8+ T Cells J. Immunol., May 1, 2009; 182(9): 5477 - 5487. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Gasteiger, W. Kastenmuller, R. Ljapoci, G. Sutter, and I. Drexler Cross-Priming of Cytotoxic T Cells Dictates Antigen Requisites for Modified Vaccinia Virus Ankara Vector Vaccines J. Virol., November 1, 2007; 81(21): 11925 - 11936. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Khan, M. S. Bijker, J. J. Weterings, H. J. Tanke, G. J. Adema, T. van Hall, J. W. Drijfhout, C. J. M. Melief, H. S. Overkleeft, G. A. van der Marel, et al. Distinct Uptake Mechanisms but Similar Intracellular Processing of Two Different Toll-like Receptor Ligand-Peptide Conjugates in Dendritic Cells J. Biol. Chem., July 20, 2007; 282(29): 21145 - 21159. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ceruti, A. Mazzola, and M. P. Abbracchio Proteasome Inhibitors Potentiate Etoposide-Induced Cell Death in Human Astrocytoma Cells Bearing a Mutated p53 Isoform J. Pharmacol. Exp. Ther., December 1, 2006; 319(3): 1424 - 1434. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Basler, J. Moebius, L. Elenich, M. Groettrup, and J. J. Monaco An Altered T Cell Repertoire in MECL-1-Deficient Mice. J. Immunol., June 1, 2006; 176(11): 6665 - 6672. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Palliser, E. Guillen, M. Ju, and H. N. Eisen Multiple Intracellular Routes in the Cross-Presentation of a Soluble Protein by Murine Dendritic Cells J. Immunol., February 15, 2005; 174(4): 1879 - 1887. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Basler, N. Youhnovski, M. van den Broek, M. Przybylski, and M. Groettrup Immunoproteasomes Down-Regulate Presentation of a Subdominant T Cell Epitope from Lymphocytic Choriomeningitis Virus J. Immunol., September 15, 2004; 173(6): 3925 - 3934. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Kono, E. Sato, H. Naganuma, A. Takahashi, K. Mimura, H. Nukui, and H. Fujii Trastuzumab (Herceptin) Enhances Class I-Restricted Antigen Presentation Recognized by HER-2/neu-Specific T Cytotoxic Lymphocytes Clin. Cancer Res., April 1, 2004; 10(7): 2538 - 2544. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Fornai, P. Lenzi, M. Gesi, M. Ferrucci, G. Lazzeri, C. L. Busceti, R. Ruffoli, P. Soldani, S. Ruggieri, M. G. Alessandri, et al. Fine Structure and Biochemical Mechanisms Underlying Nigrostriatal Inclusions and Cell Death after Proteasome Inhibition J. Neurosci., October 1, 2003; 23(26): 8955 - 8966. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. J. Wherry, J. N. Blattman, K. Murali-Krishna, R. van der Most, and R. Ahmed Viral Persistence Alters CD8 T-Cell Immunodominance and Tissue Distribution and Results in Distinct Stages of Functional Impairment J. Virol., April 15, 2003; 77(8): 4911 - 4927. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Andrieu, J.-F. Desoutter, E. Loing, J. Gaston, D. Hanau, J.-G. Guillet, and A. Hosmalin Two Human Immunodeficiency Virus Vaccinal Lipopeptides Follow Different Cross-Presentation Pathways in Human Dendritic Cells J. Virol., December 20, 2002; 77(2): 1564 - 1570. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Ros, C. J. Burckhardt, and C. Kempf Cytoplasmic Trafficking of Minute Virus of Mice: Low-pH Requirement, Routing to Late Endosomes, and Proteasome Interaction J. Virol., November 13, 2002; 76(24): 12634 - 12645. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Lomas, E. Hanon, Y. Tanaka, C. R. M. Bangham, and K. G. Gould Presentation of a new H-2Dk-restricted epitope in the Tax protein of human T-lymphotropic virus type I is enhanced by the proteasome inhibitor lactacystin J. Gen. Virol., March 1, 2002; 83(3): 641 - 650. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Khan, M. van den Broek, K. Schwarz, R. de Giuli, P.-A. Diener, and M. Groettrup Immunoproteasomes Largely Replace Constitutive Proteasomes During an Antiviral and Antibacterial Immune Response in the Liver J. Immunol., December 15, 2001; 167(12): 6859 - 6868. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Khan, R. de Giuli, G. Schmidtke, M. Bruns, M. Buchmeier, M. van den Broek, and M. Groettrup Cutting Edge: Neosynthesis Is Required for the Presentation of a T Cell Epitope from a Long-Lived Viral Protein J. Immunol., November 1, 2001; 167(9): 4801 - 4804. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Raasi, G. Schmidtke, and M. Groettrup The Ubiquitin-like Protein FAT10 Forms Covalent Conjugates and Induces Apoptosis J. Biol. Chem., September 14, 2001; 276(38): 35334 - 35343. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Kuckelkorn, T. Ruppert, B. Strehl, P. R. Jungblut, U. Zimny-Arndt, S. Lamer, I. Prinz, I. Drung, P.-M. Kloetzel, S. H.E. Kaufmann, et al. Link between Organ-specific Antigen Processing by 20S Proteasomes and CD8+ T Cell-mediated Autoimmunity J. Exp. Med., April 15, 2002; 195(8): 983 - 990. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
